Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to infuse BCMA CAR-NK cells(Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells) to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05008536
Study type Interventional
Source Xinqiao Hospital of Chongqing
Contact xi zhang, PhD/MD
Phone 13808310064
Email zhangxxi@sina.com
Status Recruiting
Phase Early Phase 1
Start date October 1, 2021
Completion date September 1, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06411301 - A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors Phase 1
Recruiting NCT06158412 - All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma Phase 2
Recruiting NCT05121103 - A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma Phase 1
Recruiting NCT04603872 - CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies Early Phase 1
Recruiting NCT04657861 - APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma Early Phase 1
Terminated NCT05191472 - Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Phase 2
Active, not recruiting NCT04688853 - A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients Phase 1
Not yet recruiting NCT05050305 - Marizomib Central Nervous System (CNS) Phase 2
Recruiting NCT05546723 - LMY-920 for Treatment of Relapsed or Refractory Myeloma Phase 1
Not yet recruiting NCT06225310 - A Trial of Selinexor, Ruxolitinib and Methylprednisolone Phase 1
Not yet recruiting NCT06115135 - A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Phase 2
Recruiting NCT05673083 - Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
Completed NCT02176213 - Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma Phase 2
Enrolling by invitation NCT04861480 - Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma Phase 1
Completed NCT06012383 - Alvocade® (Bortezomib) Safety and Effectiveness Study
Not yet recruiting NCT05909826 - Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM Phase 2
Recruiting NCT04414475 - A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM Phase 2
Completed NCT04811898 - A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment Phase 1
Recruiting NCT05739188 - Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM Phase 1/Phase 2
Recruiting NCT05747586 - BCMA CAR-NK For Patients With RRMM N/A